Boletín de AInvest
Titulares diarios de acciones y criptomonedas, gratis en tu bandeja de entrada
On April 9, 2025, Mesoblast's stock surged by 9.57% in pre-market trading, marking a significant rise that has caught the attention of investors and analysts alike.
Mesoblast Limited recently announced the availability of Ryoncil, a groundbreaking treatment that has the potential to revolutionize the medical field. However, despite this positive development, the company's stock has experienced a 15% price drop over the past week. This volatility has raised questions about the long-term prospects of
as an investment opportunity on the ASX.Analysts have set a 12-month average price target of AU$2.90 for
, indicating a potential upside for investors. This target reflects the company's innovative approach to medical treatments and its potential for growth in the market.
Titulares diarios de acciones y criptomonedas, gratis en tu bandeja de entrada
Comentarios
Aún no hay comentarios